Most Read Articles
Jairia Dela Cruz, 13 Apr 2018
Taking 10 resting blood pressure (BP) readings daily for 2 days provides a reliable, stable representation of patients’ resting systolic (S)BP and diastolic (D)BP, according to a study. This approach shows that the current home BP monitoring protocol of twice-daily readings for 4–7 days may be trimmed down to just 48 hours.
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
20 Dec 2017
Interview with Prof Peter Sever: The nocebo response during statin therapy
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.

Poor insurance coverage, costs keep patients from sticking with PCSK9 inhibitors

10 Jan 2018

Researchers from Duke University in Durham, North Carolina, US, found that up to a third of patients discontinue proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor treatment due to inadequate insurance coverage. [Navar AM, et al, AHA 2017, abstract S2112]

The results were based on a web survey of nearly 800 adults who participated in pharmaceutical company-supported online patient support groups after being prescribed PCSK9 inhibitors.

Most of the participants had tried statins at some point. At the time of the survey, 31 percent of participants were on a statin, 16.7 percent were on a high-intensity statin, and 18.8 percent were taking ezetimibe.

Eighty-seven percent of respondents (n=699) began PCSK9 inhibitor therapy when prescribed. Eighty percent of these respondents received free sample medications at some point. Sixty-six percent of respondents had approved insurance coverage for treatment but while 43 percent reported no co-pay, 16.3 percent reported paying over USD 400 per month out of pocket.

Among those who began PCSK9 inhibitor therapy, 67.7 percent remained on treatment. Those who stopped did so within 1 month (9 percent), 1–3 months (36 percent), 4–6 months (15.8 percent), and after 6 months (39.2 percent), citing insurance approval or re-approval failure (30.5 percent) and high costs (25.5 percent) as reasons.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 13 Apr 2018
Taking 10 resting blood pressure (BP) readings daily for 2 days provides a reliable, stable representation of patients’ resting systolic (S)BP and diastolic (D)BP, according to a study. This approach shows that the current home BP monitoring protocol of twice-daily readings for 4–7 days may be trimmed down to just 48 hours.
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
20 Dec 2017
Interview with Prof Peter Sever: The nocebo response during statin therapy
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.